Febuxostat combined with hydration for the prevention of contrast-induced nephropathy in hyperuricemia patients undergoing percutaneous coronary intervention: A CONSORT-compliant randomized controlled trial

BACKGROUND: To assess the efficacy of febuxostat combined with hydration on contrast-induced nephropathy (CIN) in coronary heart disease patients with hyperuricemia undergoing percutaneous coronary intervention (PCI). METHODS: Patients with hyperuricemia who underwent PCI were randomly assigned to 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Guang, Li, Min, Teng, Wei, He, Zhaohui, Zhai, Xiaojv, Xia, Zhenhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
5200
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797528/
https://www.ncbi.nlm.nih.gov/pubmed/35089218
http://dx.doi.org/10.1097/MD.0000000000028683

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797528/
https://www.ncbi.nlm.nih.gov/pubmed/35089218
http://dx.doi.org/10.1097/MD.0000000000028683

Ejemplares similares